

Supplementary Figure 2. Drugs reviewed that targeted chorea for HD in this study

Interventions	I	II	III	IV	Level
ethyl-eicosapentaenoic acid	3	1	0	0	A (No benefit)
latrepirdine*	2	0	0	0	A (No benefit)
deutetrabenazine*	1	0	0	1	B (Effective)
valbenazine*	1	0	0	0	B (Effective)
tetrabenazine	1	1	0	3	B (Effective)
physical therapy	0	3	3	2	C (Effective)
coenzyme Q10	1	1	0	0	B (no benefit)
creatine	1	2	1	2	B (no benefit)
pepinemab*	1	0	0	0	B (no benefit)
PBT2*	1	0	0	0	B (no benefit)
apomorphine*	0	1	1	0	C (Effective)
SBT-020*	0	1	0	0	C (no benefit)
selisstat*	0	1	0	0	C (no benefit)
(-)-OSU6162*	0	1	0	0	C (no benefit)
AFQ056 (mGluR5 antagonist)*	0	1	0	0	C (no benefit)
atomoxetine	0	1	0	0	C (no benefit)
bupropion	0	1	0	0	C (no benefit)
cannabidiol oral spray	0	1	0	0	C (no benefit)
citalopram	0	1	0	0	C (no benefit)
donepezil	0	1	0	1	C (no benefit)
fluoxetine	0	1	0	0	C (no benefit)
lamotrigine	0	1	0	0	C (no benefit)
nabilone*	0	1	0	0	C (no benefit)
OPC-14117*	0	1	0	0	C (no benefit)

Interventions	I	II	III	IV	Level
aripiprazole	0	0	0	1	U
deep brain stimulation	0	0	0	3	U
Diet intervention	0	0	0	2	U
fetal transplantation*	0	0	2	5	U
gene therapy (CNTF)*	0	0	0	1	U
idebenone	0	1	0	0	U
ketamine	0	0	0	1	U
levitracetam	0	0	1	0	U
memantine	0	0	0	2	U
minocycline	0	2	0	3	U
Nestacell-HD (allogeneic cell therapy)*	0	0	0	1	U
nilotinib	0	0	0	1	U
olanzapine	0	0	0	3	U
Pallidothalamic tractography	0	0	0	1	U
proglumide	0	0	0	1	U
Rilmenidine*	0	0	0	1	U
Riluzole	1	1	0	2	U
Risperidone	0	0	0	1	U
TMS	0	0	0	1	U
triheptanoin*	0	0	0	1	U
valproic acid	0	0	0	1	U
remacemide*	0	2	0	0	U (conflicting)
rivastigmine	0	1	1	0	U (conflicting)
amantadine	0	4	0	1	U (conflicting)
clozapine	0	1	0	1	U (conflicting)
pridopidine*	3	1	1	3	U (conflicting)
IONIS-HTTRx*	1	1	0	0	U (Conflicting)
cysteamine	1	0	0	2	U (conflicting)

* This medication/intervention is not available in South Korea as of Jul. 2024